Baxter International Inc (NYSE:BAX) Given Average Recommendation of “Buy” by Analysts

Shares of Baxter International Inc (NYSE:BAX) have earned an average rating of “Buy” from the twenty-one ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $96.53.

A number of brokerages have weighed in on BAX. JPMorgan Chase & Co. upped their target price on Baxter International from $94.00 to $96.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. Zacks Investment Research lowered Baxter International from a “hold” rating to a “sell” rating and set a $93.00 price objective on the stock. in a research report on Tuesday, July 7th. Raymond James reduced their price target on Baxter International from $97.00 to $95.00 and set an “outperform” rating on the stock in a research report on Friday. Piper Sandler raised their price target on Baxter International from $90.00 to $100.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Finally, Morgan Stanley reduced their price target on Baxter International from $95.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Friday.

In other Baxter International news, SVP Giuseppe Accogli sold 72,341 shares of the business’s stock in a transaction that occurred on Friday, June 19th. The stock was sold at an average price of $85.00, for a total transaction of $6,148,985.00. Following the sale, the senior vice president now directly owns 76,473 shares of the company’s stock, valued at $6,500,205. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John D. Forsyth sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $82.95, for a total value of $124,425.00. Following the sale, the director now directly owns 35,398 shares in the company, valued at $2,936,264.10. The disclosure for this sale can be found here. Insiders sold 77,583 shares of company stock worth $6,613,932 over the last quarter. 0.13% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in the stock. National Asset Management Inc. grew its stake in Baxter International by 25.0% in the second quarter. National Asset Management Inc. now owns 4,554 shares of the medical instruments supplier’s stock worth $393,000 after purchasing an additional 912 shares in the last quarter. Comerica Bank lifted its holdings in Baxter International by 17.4% during the second quarter. Comerica Bank now owns 126,075 shares of the medical instruments supplier’s stock worth $11,246,000 after buying an additional 18,687 shares during the period. Jaffetilchin Investment Partners LLC purchased a new stake in Baxter International during the second quarter worth $44,000. Lincoln National Corp lifted its holdings in Baxter International by 3.4% during the second quarter. Lincoln National Corp now owns 7,839 shares of the medical instruments supplier’s stock worth $675,000 after buying an additional 257 shares during the period. Finally, Sigma Planning Corp lifted its holdings in shares of Baxter International by 8.0% during the 2nd quarter. Sigma Planning Corp now owns 8,016 shares of the medical instruments supplier’s stock valued at $690,000 after purchasing an additional 597 shares during the last quarter. 83.74% of the stock is currently owned by institutional investors.

Shares of NYSE BAX opened at $86.38 on Friday. Baxter International has a one year low of $69.10 and a one year high of $95.19. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.74 and a quick ratio of 2.19. The business’s fifty day moving average price is $86.00 and its 200-day moving average price is $86.95. The stock has a market capitalization of $43.81 billion, a PE ratio of 26.10, a P/E/G ratio of 2.75 and a beta of 0.84.

Baxter International (NYSE:BAX) last issued its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.07). The company had revenue of $2.72 billion for the quarter, compared to analysts’ expectations of $2.86 billion. Baxter International had a return on equity of 21.02% and a net margin of 8.10%. The business’s revenue for the quarter was down 4.3% on a year-over-year basis. During the same period last year, the company posted $0.89 EPS. As a group, equities analysts expect that Baxter International will post 3.05 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Monday, August 31st will be given a $0.245 dividend. The ex-dividend date is Friday, August 28th. This represents a $0.98 dividend on an annualized basis and a dividend yield of 1.13%. Baxter International’s dividend payout ratio is currently 29.61%.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Featured Article: How are institutional investors different from individual investors?

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply